tirzepatide obstructive sleep apnea for the Treatment of and Obesity Original Article: Tirzepatide for the

Medications studied included: GLP-1 receptor agonists (e.g., semaglutide) Dual GLP/GIP agonists (e.g., tirzepatide) Other AOMs like orlistat and phentermine-topiramate After discontinuation, most participants saw measurable weight regain by the 8-, 12-, and 20-week marks

Nutritional deficiencies can impact mental health

It is important to recognise that appetite regulation is a complex physiological process influenced by multiple factors beyond GLP-1 receptor activation, including hormonal balance, metabolic rate, psychological state, sleep quality, and dietary composition

The regression results that were checked through Bayesian inference showed very similar results (Figure 3)